• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不可切除性肺癌治疗后长期存活者的特征

Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung.

作者信息

Komaki R, Cox J D, Hartz A J, Byhardt R W, Perez-Tamayo C, Clowry L, Choi H, Wilson F, Lopes da Conceicao A, Rangala N

出版信息

Am J Clin Oncol. 1985 Oct;8(5):362-70. doi: 10.1097/00000421-198510000-00005.

DOI:10.1097/00000421-198510000-00005
PMID:3933327
Abstract

Between January, 1971 and August, 1978, 410 patients with histologically or cytologically confirmed inoperable or unresectable carcinoma of the lung of all cell types were treated with curative intent. Forty-five patients lived a minimum of 3 years and 32 patients lived 5 or more years. The 3-year survival rate increased from 7.6% (15/197) between January, 1971 and June, 1975 to 14.1% (30/213) for the interval from July, 1975 to August, 1978 (p less than 0.01). Factors associated with long-term survival were performance status (p less than 0.01), early stage (p less than 0.001), high total dose of radiation (p less than 0.02), large cell carcinoma (p less than 0.01), inoperable for medical reasons (p less than 0.001), and thoracotomy to determine unresectability (p less than 0.04). The difference in survival rates between the two time periods was not related to different patient factors. Survival rates were most improved in the second time period for patients with Stage II or Stage III carcinoma of the lung. Eight patients died from cancer between 36 and 54 months of initial treatment. Five patients died of intercurrent disease without evidence of cancer of the lung after 3 years. An increasing proportion of long-term survivors of inoperable carcinoma of the lung can be expected to result from a better understanding of these diseases, more technically sophisticated external irradiation, and the use of combination chemotherapy for small cell carcinoma.

摘要

1971年1月至1978年8月期间,410例经组织学或细胞学确诊为无法手术切除或不能切除的各细胞类型肺癌患者接受了根治性治疗。45例患者至少存活了3年,32例患者存活了5年或更长时间。3年生存率从1971年1月至1975年6月期间的7.6%(15/197)上升至1975年7月至1978年8月期间的14.1%(30/213)(p<0.01)。与长期生存相关的因素包括体能状态(p<0.01)、早期阶段(p<0.001)、高总辐射剂量(p<0.02)、大细胞癌(p<0.01)、因医学原因无法手术(p<0.001)以及通过开胸手术确定无法切除(p<0.04)。两个时间段生存率的差异与不同的患者因素无关。在第二个时间段,II期或III期肺癌患者的生存率改善最为明显。8例患者在初始治疗36至54个月之间死于癌症。5例患者在3年后死于并发疾病,肺部无癌症证据。通过更好地了解这些疾病、采用技术更先进的外照射以及对小细胞癌使用联合化疗,预计无法手术切除的肺癌长期幸存者的比例将不断增加。

相似文献

1
Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung.不可切除性肺癌治疗后长期存活者的特征
Am J Clin Oncol. 1985 Oct;8(5):362-70. doi: 10.1097/00000421-198510000-00005.
2
Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.不可切除的Ⅲ期非小细胞肺癌的放化疗交替治疗:两项Ⅱ期GOTHA试验的长期结果。阿尔卑斯山胸科肿瘤学组
Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):487-94. doi: 10.1016/s0360-3016(98)00246-6.
3
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.标准剂量与高剂量适形放疗联合并巩固使用卡铂加紫杉醇,联合或不联合西妥昔单抗治疗IIIA期或IIIB期非小细胞肺癌患者(RTOG 0617):一项随机、二乘二析因3期研究。
Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.
4
Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.顺铂、依托泊苷与放疗同步治疗不可切除的Ⅲ期非小细胞肺癌:一项Ⅱ期研究。
Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):343-50. doi: 10.1016/0360-3016(96)00087-9.
5
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.非小细胞肺癌根治性放疗(>59 Gy)及同步化疗后的肺切除术
Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. doi: 10.1016/j.athoracsur.2004.04.085.
6
Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.诱导顺铂/长春碱与放疗联合应用对比单纯放疗治疗不可切除的肺鳞状细胞癌:RTOG 88-08/ECOG 4588中按细胞类型划分的失败模式。放射治疗肿瘤学组。东部肿瘤协作组。
Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):537-44. doi: 10.1016/s0360-3016(97)00365-9.
7
Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung.
Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1203-10. doi: 10.1016/0360-3016(89)90527-0.
8
Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.非小细胞肺癌病理ⅢA期(N2)三联疗法后的疾病失败模式。癌症与白血病B组方案8935分析。
Cancer. 1996 Jun 1;77(11):2393-9. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2393::AID-CNCR31>3.0.CO;2-Q.
9
Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.口服长春瑞滨和顺铂作为Ⅲ期非小细胞肺癌的诱导化疗及同步放化疗:一项国际Ⅱ期试验的最终结果
J Thorac Oncol. 2008 Sep;3(9):994-1002. doi: 10.1097/JTO.0b013e31818396cb.
10
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.III期非小细胞肺癌患者生存率的提高:癌症与白血病B组(CALGB)8433试验的七年随访
J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5. doi: 10.1093/jnci/88.17.1210.

引用本文的文献

1
Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.纳入治疗前外周血标志物的非小细胞肺癌患者总生存预测列线图。
Eur J Cardiothorac Surg. 2018 Jun 1;53(6):1214-1222. doi: 10.1093/ejcts/ezx462.
2
Assays for predicting and monitoring responses to lung cancer immunotherapy.预测和监测肺癌免疫治疗反应的检测方法。
Cancer Biol Med. 2015 Jun;12(2):87-95. doi: 10.7497/j.issn.2095-3941.2015.0019.
3
18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
18F-FDG PET用于评估Ⅲ期非小细胞肺癌新辅助放化疗后的治疗反应及术前重新评估。
Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):463-71. doi: 10.1007/s00259-006-0273-5. Epub 2006 Nov 14.
4
Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?标准化的(18)F-FDG摄取值是Ⅲ期非小细胞肺癌患者的预后预测指标吗?
Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):263-9. doi: 10.1007/s00259-005-1953-2. Epub 2005 Nov 4.
5
Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group.非小细胞肺癌症状的缓解:约克郡地区癌症组织胸科组的一项研究
Thorax. 1993 Apr;48(4):339-43. doi: 10.1136/thx.48.4.339.
6
Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party.不可切除的非小细胞肺癌(NSCLC):医学研究委员会关于两分割与十分割姑息性放疗的随机试验。医学研究委员会肺癌工作组向其提交的报告
Br J Cancer. 1991 Feb;63(2):265-70. doi: 10.1038/bjc.1991.62.